GeoVax Labs, Inc. – NASDAQ:GOVXW

GeoVax Labs stock price today

$0.022
-0.08
-80.18%
Financial Health
0
1
2
3
4
5
6
7
8
9

GeoVax Labs stock price monthly change

+34.15%
month

GeoVax Labs stock price quarterly change

+34.15%
quarter

GeoVax Labs stock price yearly change

+216.18%
year

GeoVax Labs key metrics

Market Cap
25.66M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-14.45
Revenue
N/A
EBITDA
-28.27M
Income
-27.77M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-22925.62%
Oper. margin
-22936.36%
Gross margin
0%
EBIT margin
-22936.36%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

GeoVax Labs stock price history

GeoVax Labs stock forecast

GeoVax Labs financial statements

GeoVax Labs, Inc. (NASDAQ:GOVXW): Profit margin
Jun 2023 0 -5.92M
Sep 2023 0 -8.40M
Dec 2023 103.91K -7.59M -7306.57%
Mar 2024 0 -5.85M
GeoVax Labs, Inc. (NASDAQ:GOVXW): Debt to assets
Jun 2023 21249062 4.08M 19.23%
Sep 2023 16201031 7.08M 43.71%
Dec 2023 9283219 3.51M 37.92%
Mar 2024 3358182 3.30M 98.38%
GeoVax Labs, Inc. (NASDAQ:GOVXW): Cash Flow
Jun 2023 -6.03M -23.80K 0
Sep 2023 -5.09M -6.19K 0
Dec 2023 -10.27M -18.94K 4.06M
Mar 2024 -5.68M 0 0

GeoVax Labs alternative data

GeoVax Labs, Inc. (NASDAQ:GOVXW): Employee count
Jan 2024 14
Feb 2024 14
Mar 2024 17
Apr 2024 17
May 2024 17
Jun 2024 17
Jul 2024 17

GeoVax Labs other data

0.00% -1.40%
of GOVXW is owned by hedge funds
151 -85.48K
shares is hold by hedge funds
  • What's the price of GeoVax Labs stock today?

    One share of GeoVax Labs stock can currently be purchased for approximately $0.02.

  • When is GeoVax Labs's next earnings date?

    Unfortunately, GeoVax Labs's (GOVXW) next earnings date is currently unknown.

  • Does GeoVax Labs pay dividends?

    No, GeoVax Labs does not pay dividends.

  • How much money does GeoVax Labs make?

    GeoVax Labs has a market capitalization of 25.66M.

  • What is GeoVax Labs's stock symbol?

    GeoVax Labs, Inc. is traded on the NASDAQ under the ticker symbol "GOVXW".

  • What is GeoVax Labs's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of GeoVax Labs?

    Shares of GeoVax Labs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does GeoVax Labs have?

    As Jul 2024, GeoVax Labs employs 17 workers.

  • What is GeoVax Labs's official website?

    The official website for GeoVax Labs is geovax.com.

  • How can i contact GeoVax Labs?

    GeoVax Labs can be reached via phone at +678 3847220.

GeoVax Labs company profile:

GeoVax Labs, Inc.

geovax.com
Exchange:

NASDAQ

Full time employees:

17

Industry:

Biotechnology

Sector:

Healthcare

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

1900 Lake Park Drive
Smyrna, 30080

CIK: 0000832489
ISIN: US3736781192
CUSIP: 373678119